Otorhinolaryngology-Head & Neck Surgery
Microbiology and Immunology
Chair, Department of Otorhinolaryngology - Head & Neck Surgery
Education and Training
- Dartmouth College, BA, Liberal Arts, 1987
- Harvard Medical School, MD, Medicine, 1991
- Residency, Department of Otorhinolaryngology-Head and Neck Surgery, University of Michigan Medical Center, 1997
- Fellowship, Department of Otorhinolaryngology, Allegheny Health Education and Research Foundation, 1998
- Mentorship, Dr. Lieping Chen, Mayo Clinic, 2003
Scott Strome, MD, is Professor and Chairman of the Department of Otorhinolaryngology and Interim Chairman of the Department of Dermatology at the University of Maryland School of Medicine. He previously served as Interim Chairman of the Department of Ophthalmology and Visual Sciences and as founder/former leader of the program in tumor immunology and immunotherapy within the Marlene and Stewart Greenebaum Cancer Center.
Dr. Strome is an internationally recognized head and neck surgeon, with particular expertise in the treatment of head and neck tumors, thyroid cancer, and diseases of the anterior skull base. He has contributed nationally as chairman of two NIH special emphasis panels and membership on the Recombinant DNA Advisory Committee. He has excelled in creating drugs and procedures with direct clinical impact. For example, as a Harvard Medical Student, Dr. Strome worked with his father and developed the in vivo models that ultimately resulted in the first human larynx transplant.
Similarly, at the Mayo Clinic, Dr. Strome worked with Lieping Chen, MD, to define the translational potential of two costimulatory molecules, B7-H1 (PDL-1) and 4-1BB. The papers resulting from this collaboration are considered seminal works in the field and the intellectual property portfolio on the use of B7-H1, many patents on which Drs. Strome and Chen are named as inventors, has translated into the successful use of these drugs for the treatment of cancer.
Finally, Dr. Strome has co-developed a new series of Trojan Peptide Vaccines (TPV) for cancer and evaluated their utility in phase I/II clinical trials. These TPVs, in combination with fully recombinant intravenous immunoglobulin mimetics, serve as core technologies for a biotechnology company, Gliknik Inc., of which Dr. Strome is co-founder. In recognition of these academic-industry initiatives, the University of Maryland Baltimore recognized Dr. Strome as the "2011 Entrepreneur of the Year," and he was named as Entrepreneur of the year for the University of Maryland in 2013. These scientific endeavors have also resulted in 117 publications in leading basic science and clinical journals.
Squamous Cell Carcinoma, Specific Tumor Antigens, Antigen Specific Vaccines, Bone Marrow Derived Effector Cells, Antitumor Therapy
My interest in science was kindled as a Harvard Medical Student, where I worked with my father, Marshall Strome, MD, to develop the in vivo models that ultimately resulted in the first human larynx transplant – performed by my dad. Notably, these studies also played an important role in addressing the societal hurdles facing non-essential organ transplantation.
- Strome S, Brodsky G, Darrell J, Wu J, Strome M. Histopathologic correlates of acute laryngeal allograft rejection in a rat model. Annals of Otology, Rhinology and Laryngology. 101:156-160, 1992. PMID:1739261
- Strome S, Sloman-Moll E, Samonte BR, Wu J, Strome M. A rat model for a vascularized laryngeal allograft. Annals of Otology, Rhinology and Laryngology. 101:950-953, 1992. PMID:1444103
- Strome S, Strome M. Laryngeal transplantation: Ethical considerations. American Journal of Otolaryngology. 13:75-77, 1992. PMID:1642330
- Strome M, Strome S, Darrell J, Wu J, Brodsky G, The effects of cyclosporin A on transplanted rat allografts. The Laryngoscope. 103:394-398, 1993. PMID:8459748
As a faculty member in the Department of Otolaryngology-Head & Neck Surgery at the Mayo Clinic College of Medicine, I worked with Lieping Chen, MD, (Credited with identifying the B7-H family) first as a mentee and subsequently as a close collaborator, to help define the translational potential of two costimulatory molecules, B7-H1 (PD-L1, CD274) and 4-1BB (CD137). The papers resulting from this collaboration are considered seminal works in the field and the intellectual property portfolio on the use of B7-H1, many patents on which Drs. Strome and Chen are named as inventors, has resulted in a new paradigm for the treatment of cancer.
- Dong H, Strome SE, Salomao DR, Flies DB, Kobayashi H, Lennon VA, Celis E and Chen L. Tumour-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine. 8:793-800, Aug 2002. PMID:12091876
- Strome SE,Dong HD, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Hirano F, Lin W, Kasperbauer JL, Ballman KV, Chen L. B7-H1 Blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Research. 63(19):6501-6505, 2003. PMID:14559843
- Dong H, Strome S, Matteson E,Moder K, Flies D, Zhu G, Tamura H, Driscoll C, Chen L. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. Journal of Clinical Investigation. 111(3):363-370, Feb 2003.PMID:12569162 (Dr. Strome and Dr. Dong share first authorship.)
- Thompson RH, Gillette MD, Cheville JC, Lohse C, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, Zincke H, Blute MJ, Strome SE, Leibovich B, Kwon ED. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences. 101:17174-17179, 2004. PMID:15569934
I co-developed two Trojan peptide vaccines (TPVs) and conducted an NIH funded phase I clinical trial employing these drugs for the treatment of advanced head and neck cancer (SCCHN). These TPVs have now been evaluated in a dose escalation study in SCCHN and by collaborators at the University of Pennsylvania and the UMSOM as part of a multi-faceted approach for the treatment of multiple myeloma. A pivotal trial for the prevention of recurrent disease in patients with advanced oral cavity malignancies is in the advanced planning stages. It is my hope that these drugs will offer a cost-efficient, effective means to prevent tumor recurrence in individuals for whom no other options exist.
- Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam, Gastman B, Papadimtriou J, Lu C, Tan M, Morales R, Cullen K, Celis E, Mann D, Strome SE. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patient with head and neck carcinoma. Head Neck. 2012 Dec;34(12):1734-46 (Figure 2A-C was chosen as the cover figure) PMID: 22287423
- Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang H-B, Weiss BM, Badros A, Yanovich S, Akpek G, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH. Combination immunotherapy after ASCT for multiple myeloma (MM) using MAGE-A3/Poly-ICLC immunizations followed by vaccine-primed and costimulated autologous T-Cells. Clinical Cancer Research, 2014; 20(5):1355-65. PMID: 24520093
- Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, Ord R, Lubek JE, Suntharalingam M, Papadimitriou JC, Mann D, Strome SE*, Edelman MJ*. A Phase I Dose Escalation Trial of MAGE-A3 and HPV16 Specific Peptide Immunomodulatory Vaccines in Patients with Recurrent / Metastatic (RM) Squamous Cell Carcinoma of the Head and Neck (SCCHN) *Shared senior authorship. Cancer Immunology and Immunotherapy. 2015; 64(3):367-379. PMID:25537079
I co-developed a series of fully recombinant Fc multimers, called stradomersTM, based on the concept that Fc bearing immune aggregates are a natural means to limit inflammation. This new class of drugs, that are designed to mimic the anti-inflammatory properties of intravenous immunoglobulin (IVIG), show profound anti-inflammatory properties in in vitro and in vivo. From a clinical perspective, I am optimistic that these drugs will provide a safe, low cost alternative to IVIG. In addition, they can be employed as molecular tools to carefully delineate the effects of the Fc fragments of antibodies on inflammation.
- Jain AJ, Olsen HS, Vyzasatya R, Burch E, Sakoda Y, Merigeon EY, Cai L, Lu C, Tan M, Tamada K, Schulze D, Block DS, Strome SE. Fully recombinant IgG2a Fc multimers (StradomersTM) effectively treat collagen induced arthritis and prevent idiopathic thrombocytopenic in mice. Arthritis Research and Therapy. 14(4):R192, 2012. PMID:22906120
- Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer. Eur J Cancer. 2013 Oct; 49(15):3344-52. PMID: 23871153
- Zhang X, Olsen HO, Chen S, So E, Zhou H, Burch E, Merigeon EY, Block DS, Strome SE. -CD20 antibodies with multimerized Fc domains: A novel strategy to deplete B cells and augment treatment of autoimmune disease. Journal of Immunology, 196:1165-1176, 2016. PMID: 26695368.
Dr. Strome's research program is focused on the study of mechanisms to harness the immune response to squamous cell carcinoma of the head and neck (SCCHN) for purposes of diagnoses/monitoring and therapy. From a diagnostic perspective, Dr. Strome’s laboratory is studying the humoral response to specific tumor antigens both as a prognostic indicator and as tool to identify antigen specific T cell function.
The therapeutic component of Dr. Strome’s research is geared toward the development of antigen specific vaccines to stimulate priming of the immune response with subsequent manipulation of specific costimulatory pathways to enhance antitumor effector T cell function. These studies include characterizing the protein structure and function of costimulatory molecules at the molecular level and assessing their suitability for clinical use.
Additionally, Dr. Strome’s laboratory is developing means to determine the utility of bone marrow derived effector cells for antitumor therapy. Dr. Strome’s laboratory is funded by a combination of extramural, industry, institutional and philanthropic support.
- Mildred Mindell Cancer Foundation Award, 2007
- Presidential Citation, American Laryngological Association, 2008
- University of Maryland Baltimore -- Entrepreneur of the Year, 2011
- US News and World Report "Top Doctors,” 2011, 2012
- University of Maryland -- Entrepreneur of the Year, 2013
- Alpha Omega Alpha Honor Medical Society, 2014
- University of Maryland, Department of OTO-HNS, Brian E. Emery, MD Outstanding Teaching Award, 2014
Associate Professor of Otorhinolaryngology, Mayo Medical School, 2002-2004